Study Summary
This trial is designed to study how well the Eversense CGM system works compared to self-monitoring of blood sugar in managing diabetes. The study will last for 12 months and will include clinic visits and home use of the Eversense CGM system.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: First 6 months (phase 1) compared to second 6 months (phase 2)
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Self monitoring of blood glucose, then CGM System
1 of 1
Experimental Treatment
925 Total Participants · 1 Treatment Group
Primary Treatment: Eversense CGM System · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 13th, 2021
Last Reviewed: November 21st, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Maryland | 50.0% |
| Florida | 25.0% |
| Tennessee | 25.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| The Center for Diabetes and Endocrine Care | 33.3% |
| Atlanta Diabetes Associates | 33.3% |
| Southern Maryland Medical Group | 33.3% |
What portion of applicants met pre-screening criteria?
| Met criteria | 75.0% |
| Did not meet criteria | 25.0% |